| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Eletriptan | Eletriptan Impurity A | VL990004 | View |
| Eletriptan | Eletriptan Impurity B | VL990005 | View |
| Eletriptan | Eletriptan Impurity D | VL990006 | View |
| Eletriptan | Eletriptan Impurity L | VL990007 | View CAS 1217641-89-8 |
| Eletriptan | Eletriptan Related Compound 01 | VL990003 | View CAS 1252673-29-2 |
| Eletriptan | Eletriptan Related Compound 02 | VL990002 | View CAS 188113-71-5 |
| Eletriptan | Eletriptan Related Compound 03 | VL990001 | View CAS 209682-64-4 |
| Catalogue No. | VL990007 |
| CAS No. | 1217641-89-8 |
| Molecular Formula | C22H26N2O3S |
| Molecular Weight | 398.52 |
| Parent drug | Eletriptan |
| IUPAC Name | 3-[[(2R)-1-Methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole N-Oxide |
| Synonyms | Eletriptan N-Oxide |
| References | "Goadsby, P. J., et al. “Eletriptan in Acute Migraine: A Double-Blind, Placebo-Controlled Comparison to Sumatriptan.” Neurology, vol. 54, no. 1, Jan. 2000, pp. 156–56, https://doi.org/10.1212/wnl.54.1.156. ?McCormack, Paul L., and Gillian M. Keating. “Eletriptan.” Drugs, vol. 66, no. 8, 2006, pp. 1129–49, https://doi.org/10.2165/00003495-200666080-00010. ?" |
| Status | In-stock |
| ListName | Eletriptan Impurity L |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
